argenx SE American Depositary Shares (ARGX) Financial Statements

argenx SE American Depositary Shares

ARGX · NASDAQ-GS

	FY2019	FY2018	FY2017
Net Income	-$162.97M	-$66.64M	-$28.08M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$28.05	$25.10	$33.07	8	↑6 ↓0
Dec 2027	$35.77	$29.64	$42.91	12	↑8 ↓1
Dec 2028	$45.73	$38.74	$55.82	8	↑5 ↓0
Dec 2029	$57.08	$43.43	$75.19	5	↑4 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: ARGX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: Europe
Exchange: NASDAQ-GS

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Analyst Consensus

See all

Buy

25 analysts

$864

Current

—

Low

$1,060

Average

—

High

Average target implies +22.67% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series ABRKRP · NASDAQ-GS$390.77